LINCOSEAMIDES (Veterinary—Systemic)

This monograph includes information on the following: Clindamycin; Lincomycin.

Some commonly used brand names are:

- **Antirobe Aquadrops**
  - [Lincomycin](Lincomycin)
- **Antirobe Capsules**
  - [Lincomycin](Lincomycin)
- **Clincaps** [Lincomycin]
  - Lincomox 100
- **ClindaCare Capsules** [Clindamycin]
  - Lincomox 50 Feed Medication
- **ClindaCare Oral Liquid** [Clindamycin]
  - Lincomix Injectable
- **Clinda-Guard Oral Liquid** [Clindamycin]
  - Lincomix 44 Premix
- **Clindrops** [Clindamycin]
  - Lincomix 110 Premix
- **Clinsol** [Clindamycin]
  - Lincomix Soluble Powder
- **Clintabs** [Clindamycin]
  - Lincomycin 44G Premix
- **Lincoin Aquadrops** [Lincomycin]
  - Lincomix 11 Premix
- **Lincoin Sterile Solution** [Lincomycin]
  - Lincosol Soluble Powder
- **Lincoin Tablets** [Lincomycin]
  - nvClindamycin Capsules
- **Linco-Ject 300** [Lincomycin]

Note: For a listing of dosage forms and brand names by country availability, see the **Dosage Forms** section(s).

Category: Antibacterial (systemic).

Indications

Note: The text between 
\[\text{R-1; } 3; 30\] describes uses that are not included in U.S. product labeling. Text between 
\[\text{R-1; } 3; 30\] and 
\[\text{R-4; 5}\] describes uses that are not included in Canadian product labeling.

The \[\text{R-1; } 3; 30\] or \[\text{R-4; 5}\] designation can signify a lack of product availability in the country indicated. See the **Dosage Forms** section of this monograph to confirm availability.

General considerations

The lincomesides have activity against many gram-positive bacteria and many anaerobic bacteria, but are not effective against most gram-negative organisms.

Lincomycin has been shown to have efficacy against *Erysipelothrix rhusiopathiae*, *Leptospira pomona*, *Mycoplasma* species, *Staphylococcus* species, and *Streptococcus* species (except *Streptococcus faecalis*). The activity of lincomycin against obligate anaerobes is seldom addressed in published literature; one exception is *in vitro* activity against *Fusobacterium necrophorum*. \[\text{R-46}\] According to the National Committee for Clinical Laboratory Standards in the United States, clindamycin is the class antibiotic for the lincomadine family and the clindamycin disk is used in *in vitro* testing to assess susceptibility to both clindamycin and lincomycin. \[\text{R-39}\] Therefore, it is presumed that most anaerobes susceptible to clindamycin would likewise be susceptible to lincomycin, provided compensations for potency and kinetic disposition are made. \[\text{R-39}\]

Clindamycin has a spectrum of activity that includes *Mycoplasma* species, *Staphylococcus* species, and *Streptococcus* species (except *Streptococcus faecalis*), as well as anaerobic organisms, such as *Actinomyces* species, *Bacteroides* species, *Clostridium perfringens* (but not necessarily other clostridia), *Fusobacterium* species, *Peptostreptococcus* species, and *Propionibacterium* species.

**Accepted**

Dental infections (treatment)—

- **Cats:** Clindamycin oral solution is indicated in the treatment of dental infections caused by susceptible bacteria. \[\text{R-4; 5}\]
- **Dogs:** Clindamycin capsules, oral solution, and ELUS tablets are indicated in the treatment of dental infections caused by susceptible bacteria. \[\text{R-4; 1; 2; 62}\]

Dentistry, swine (treatment)—**Pigs:** Lincomycin hydrochloride for medicated feed, soluble powder, and ELUS injection are indicated in the treatment and control of swine dysentery caused by susceptible organisms. \[\text{R-4; 4; 20; 30; 38; 41; 42}\]

Enteritis, necrotic (treatment)—**Chickens:** Lincomycin hydrochloride for medicated feed is indicated in the control of necrotic enteritis in chickens caused by susceptible organisms, such as *Clostridium perfringens*. \[\text{R-6; 20; 30; 38; 41; 42}\]

Growth promotion and feed efficiency, increased—**Chickens and pigs:** Lincomycin hydrochloride for medicated feed is indicated for increased weight gain in growing-finishing pigs and for increased weight gain and feed efficiency in broiler chickens. \[\text{R-4; 38; 42}\]

Joint infections (treatment)—**Pigs:** Lincomycin injection is indicated in the treatment of infectious arthritis caused by susceptible organisms, including susceptible *Staphylococcus* species, *Streptococcus* species, *Erysipelothrix rhusiopathiae*, and *Mycoplasma* species. \[\text{R-4; 5}\]

**ELUS**

- **Metritis (treatment)**—**Dogs:** Lincomycin injection, syrup, and tablets are indicated in the treatment of metritis caused by susceptible organisms. \[\text{R-3}\]

Osteomyelitis (treatment)—**Dogs:** Clindamycin capsules, and oral solution, and ELUS tablets are indicated in the treatment of osteomyelitis caused by susceptible organisms, such as *Staphylococcus aureus*. \[\text{R-3}\]

Pneumonia, bacterial (treatment)—**Pigs:** ELUS Clindamycin injection and lincomycin hydrochloride for medicated feed are indicated in the treatment of pneumonia caused by susceptible *Mycoplasma* species. \[\text{R-4; 5; 42}\]

Porcine proliferative enteropathies (treatment)—**Pigs:** Lincomycin hydrochloride for medicated feed is indicated in the control of porcine proliferative enteropathies (ileitis) caused by *Lawsonia intracellularis*. \[\text{R-4; 6; 42}\]

**ELUS**

- **Respiratory tract infections (treatment)**—
  - **Cats:** Lincomycin injection, syrup, and tablets are indicated in the treatment of respiratory tract infections caused by susceptible organisms. \[\text{R-3}\]
  - **Dogs:** Lincomycin injection, syrup, and tablets are indicated in the treatment of respiratory tract infections caused by susceptible organisms. \[\text{R-3}\]

**ELUS**

- **Skin infections (treatment)**—**Dogs:** Lincomycin injection, syrup, and tablets are indicated and ELUS clindamycin \[\text{R-20}\] is effective in the treatment of skin infections, such as pustular dermatitis, caused by susceptible organisms. \[\text{R-3}\]
  
  To assure efficacy in the treatment of skin infections, underlying primary disorders, such as allergic inhalant dermatitis, should be identified and controlled. \[\text{R-4; 41; 42}\]

Soft tissue infections (treatment)—

- **Cats:** Clindamycin oral solution and ELUS lincomycin injection, syrup, and tablets are indicated in the treatment of soft tissue infections, including abscesses, caused by susceptible organisms. \[\text{R-4; 3; 30}; 41; 42]\n
© 2008 The United States Pharmacopeial Convention
Osteomyelitis (treatment) – ELUS,CAN

**Molecular weight:**

**Molecular formula:**

**Source:**

Chemistry

U.S. and Canada —

**Regulatory Considerations**

**Chemistry**

**Source:**

- Clindamycin hydrochloride — 7(S)-Chloro derivative of lincomycin.[R-27]
- Lincomycin hydrochloride — Produced by the growth of a member of the *Lincolnus* group of *Streptomyces* (family *Streptomycetaceae*).[R-5]

**Chemical name:**

- Clindamycin hydrochloride—L-threo-alpha-n-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[1-methyl-4-propyl-2-pyrrolidiny]carboxy]amino]-1-thio-, (2S-trans), monohydrochloride.[R-25]
- Lincomycin hydrochloride—D-erythro-alpha-n-galacto-Octopyranoside, methyl 6,8-dideoxy-6-[[1-(methyl-4-propyl-2-pyrrolidiny)carboxy]amino]-1-thio-, monohydrochloride, monohydrate, (2S-trans).[R-25]

**Molecular formula:**

- Clindamycin hydrochloride—C_{18}H_{34}N_{2}O_{6}S⋅HCl.[R-25]
- Lincomycin hydrochloride—C_{18}H_{27}NO_{5}S⋅HCl⋅H_{2}O.[R-25]

**Molecular weight:**

- Clindamycin hydrochloride—461.44.[R-25]
- Lincomycin hydrochloride—461.01.[R-25]

**Description:**

- Clindamycin Hydrochloride USP—White or practically white, crystalline powder. Is odorless or has a faint mercaptan-like odor. Is stable in the presence of air and light. Its solutions are acidic and are dextrorotatory.[R-26]
- Lincomycin Hydrochloride USP—White or practically white, crystalline powder. Is odorless or has a faint odor. Is stable in the presence of air and light. Its solutions are acid and are dextrorotatory.[R-26]

**pKa:**

- Clindamycin—7.7.[R-14]
- Lincomycin—7.6.[R-14]

**Solubility:**

- Clindamycin Hydrochloride USP—Freely soluble in water, in dimethylformamide, and in methanol; soluble in alcohol; practically insoluble in acetone.[R-26]
- Lincomycin Hydrochloride USP—Freely soluble in water; soluble in dimethylformamide; very slightly soluble in acetone.[R-26]

**Pharmacology/Pharmacokinetics**

**Mechanism of action/Effect:**

The lincosamides inhibit protein synthesis in susceptible bacteria by binding to the 50 S ribosomal subunits of bacterial ribosomes and preventing peptide bond formation.[R-43] The lincosamides are usually considered bacteriostatic;[R-44] however, when clindamycin is present at sufficient concentrations, it may act as a bactericidal antibiotic against sensitive organisms.[R-43]

**Other actions/effects:**

Clindamycin may interfere with the attachment and entry of Toxoplasma gondii tachyzoites into host cells.[R-33]

**Absorption:**

Oral absorption of the lincosamides is rapid, but orally administered lincomycin is less well absorbed than clindamycin. Clindamycin—Oral absorption of clindamycin is high[R-25] and is unaffected by food.

**Distribution:**

Clindamycin and lincomycin are widely distributed into most tissues, including respiratory tissue, soft tissue, bones, and joints.[R-13; 21; 24] The lincosamides are weak bases (commercial preparations are acidic) and are very lipid soluble at physiologic pH (7.4). Tissue concentrations may be higher than serum concentrations.[R-40] Small amounts are distributed into pancreatic and prostatic secretions.[R-48] There is evidence that clindamycin hydrochloride accumulates in polymorphonuclear granulocytes.[R-20] The lincosamides do not penetrate cerebrospinal fluid (CSF) well;[R-24] however, in healthy cats, concentrations of clindamycin in brain tissue after 10 days of therapy were 10 to 20% of serum concentration and were consistently higher than CSF concentrations.[R-24]

Volume of distribution (area)—Intravenous administration:

- Clindamycin phosphate—Dogs: 1.4 L per kg (L/kg).[R-14]
- Lincomycin—Calves: 6 weeks of age—1 to 1.2 L/kg (healthy calves or calves with induced Pasteurella haemolytica pneumonia).[R-40]
- 9 months of age—1.3 L/kg.[R-47]

**Protein binding:**

- Clindamycin—Sheep: Moderate (40 to 50%).[R-14; 51]
- Lincomycin—
  - Cows—Low to moderate (26 to 46%).[R-52]

Dogs: Clindamycin capsules, oral solution, and [USAN, tablets][R-1, 4; and ELUS,CAN, injection, syrup, and tablets][R-1, 2] are indicated in the treatment of soft tissue infections, including abscesses and infected wounds, caused by susceptible organisms.[R-1, 13, 22]

Potentially effective[ELUS,CAN] infections, bacterial (treatment)[R-1] — Cattle: Although there are insufficient data to establish safety and efficacy, lincomycin injection may be used in combination with other antibiotics to provide a wide range of coverage to treat susceptible infections that may involve aerobes resistant to more commonly used medications or anaerobes, including *Bacteroides* spp.[R-14; 46; 66]

Metritis (treatment)—Dogs: There are insufficient data to confirm the efficacy of [ELUS,CAN] clindamycin[R-1] in the treatment of metritis in dogs; however, because lincomycin is indicated for this use, clindamycin can be expected to be at least equally effective.[R-15] Insufficient data to establish the efficacy of clindamycin in the treatment of metritis in cats; however, the safety and predicted antimicrobial efficacy are supported by research.[R-24; 53; 54; 57]

Respiratory tract infections (treatment)—Cats and dogs: There are insufficient data to confirm the efficacy of [ELUS,CAN] clindamycin[R-1] in the treatment of respiratory infections in cats and dogs; however, because lincomycin is indicated for this use, clindamycin can be expected to be at least equally effective.[R-15] Insufficient data to establish the efficacy of clindamycin in the treatment of *Toxoplasma gondii* infection in cats; however, it is considered to have fewer side effects and perhaps to be more effective in treating some aspects of the disease than is pyrimethamine.[R-17; 19; 34; 90] Insufficient data to establish the efficacy of clindamycin in the treatment of Toxoplasmosis (treatment)EL—

Lincosamides do not penetrate the cerebrospinal fluid (CSF) well; however, in healthy cats, concentrations of clindamycin in brain tissue after 10 days of therapy were 10 to 20% of serum concentration and were consistently higher than CSF concentrations.[R-24]

Volume of distribution (area)—Intravenous administration:

- Clindamycin phosphate—Dogs: 1.4 L per kg (L/kg).[R-14]
- Lincomycin—Calves: 6 weeks of age—1 to 1.2 L/kg (healthy calves or calves with induced Pasteurella haemolytica pneumonia).[R-40]
- 9 months of age—1.3 L/kg.[R-47]

Protein binding:

- Clindamycin—Sheep: Moderate (40 to 50%).[R-14; 51]
- Lincomycin—
  - Cows—Low to moderate (26 to 46%).[R-52]
Elimination:

Duration of action:

Serum concentrations:

Time to peak concentration:

Half-life:

Biotransformation:

Lincomycin—The percentage of administered lincosamide metabolized by the liver is unknown.[R-49]

Clearance—Intravenous administration:

Note: Efficacy studies based on a 22 mg/kg dose every 12 hours.

Dogs:

Clindamycin—Intramuscular—1 hour (dose of 20 mg/kg).[R-16]

Clindamycin phosphate—Intramuscular—1 hour (dose of 11 mg/kg).[R-16]

Lincomycin hydrochloride—Oral—1.25 hours (single dose of 5.5 to 11 mg/kg).[R-1]

Sheep:

Clindamycin phosphate—Intramuscular—1 hour (dose of 20 mg/kg).[R-16]

Lincomycin—Newborn to 2 weeks of age—3 hours.[R-47]

Calves, 4 weeks to 9 months of age—2 to 2.5 hours.[R-46; 47]

Durations of action:

Clindamycin—Cats and dogs.[R-15]

12 hours, with an oral dose of 11 mg/kg.

24 hours, with an oral dose of 22 mg/kg.

Lincomycin—Dogs: Oral—for gram-positive organisms: 6 to 8 hours (22 mg/kg dose).[R-3]

Note: Efficacy studies based on a 22 mg/kg dose every 12 hours for 3 weeks in dogs show that duration of action for lincomycin is sufficient for it to be effective when administered every twelve hours.[R-20]

Elimination:

Parent drug and metabolites are primarily excreted in the urine and the bile.[R-1; 24; 46; 49] Small amounts are excreted in intestinal contents and pancreatic and prostatic fluids.[R-48]

When lincomycin is administered orally to dogs, 77% of the dose is excreted in the feces and 14% of the dose is excreted in the urine. When administered intramuscularly, 38% of the dose is excreted in the feces and 49% is excreted in the urine.[R-3]

Less clindamycin than lincomycin is excreted in the urine.[R-3]

Clearance—Intravenous administration:

Clindamycin phosphate—Dogs: 5.3 mL per minute per kg (mL/ min/kg).[R-18]

Lincomycin—Calves:

6 weeks of age—3.9 to 8.1 mL/min/kg.[R-46]

9 months of age—4.4 mL/min/kg.[R-46]

Precautions to Consider

Cross-sensitivity and related problems

Animals sensitive to clindamycin may be sensitive to lincomycin and the reverse may also be true.

Species sensitivity

Chinchillas, guinea pigs, hamsters, horses, ponies, and rabbits: The use of oral clindamycin or lincomycin is generally contraindicated in these species because of the risk of altering the gastrointestinal microflora and causing serious or fatal enterocolitis and diarrhea.[R-7; 9; 11] Overgrowth of organisms such as Clostridium or Salmonella species has been suspected as the cause in many species. Cecal Escherichia coli, but not Clostridium species, have been cultured from rabbits showing adverse effects after lincomycin exposure.[R-44] Contamination of feed with lincomycin at or below feed additive concentrations used for pigs has caused severe or fatal diarrhea in rabbits, ponies, and horses.[R-7; 9]

Ruminants: Ruminants exposed to oral lincomycin have also been reported to have side effects such as anorexia, ketosis, and sometimes severe diarrhea,[R-4; 10; 12; 50] possibly caused by overgrowth of nonsusceptible bacterial; however, case reports and research studies using parenteral lincomycin have reported that only a small percentage of treated animals developed diarrhea and/or decreased milk production.[R-44; 47]

Feeds contaminated with 3 to 24 parts per million (ppm) of lincomycin have caused ketosis and diarrhea in dairy cows.[R-12] After treatment with oral lincomycin for Campylobacter, two thirds of a range flock of sheep died; however, the flock had a history of Salmonella infections and grazed in an area with some oxalate-containing range plants, both of which were believed to play a role in the losses.[R-18]

Pregnancy/Reproduction

The safety of clindamycin in pregnant or breeding animals has not been established.[R-1; 2; 13]

When lincomycin was given to pregnant dogs at 50 mg per kg of body weight (mg/kg) per day, no evidence of teratogenic effects on the embryos was seen.[R-3] Also, 75 mg of lincomycin per kg a day administered to breeding male and female rats during a breeding cycle had no observed effect on breeding or teratogenic effects on offspring.[R-3]

Lactation

Clindamycin and lincomycin are distributed into milk in therapeutic concentrations.[R-14; 40] With constant serum lincomycin concentrations, milk concentrations range from 2.5 to 6.2 times the serum concentration, depending on the pH of the milk.[R-14]

Pediatrics

No evidence of side effects was noted in newborn puppies and rats given lincomycin at doses of 30 to 90 mg/kg a day.[R-3]

Drug interactions and/or related problems

The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate)—not necessarily inclusive (» = major clinical significance):

Note: Combinations containing any of the following medications, depending on the amount present, may also interact with this medication.

» Anesthetics, hydrocarbon inhalation, such as:

Enflurane

Halothane

Isoflurane

© 2008 The United States Pharmacopeial Convention

All rights reserved
The following laboratory value alterations have been reported in humans, and are included in the human monographs Clindamycin (Systemic) and Lincomycin (Systemic) in USP DI Volume I; these laboratory value alterations are intended for informational purposes only and may or may not be applicable to the use of clindamycin and lincomycin in the treatment of animals:

**Antidiarrheals, adsorbent**
- (concurrent use of kaolin- or attapulgite-containing antidiarrheals with oral lincomycin may significantly decrease absorption of oral lincomycin; concurrent use with oral clindamycin may delay absorption; concurrent use should be avoided or patients should be advised to take adsorbent antidiarrheals not less than 2 hours before or 3 to 4 hours after oral lincosamides)

**Antidiarrheals, antiperistaltic**
- (antiperistaltic agents, such as opiates, difenoxin, diphenoxylate, or loperamide, may prolong or worsen pseudomembranous colitis by delaying toxin elimination)

**Antimyasthenics**
- (concurrent use of medications with neuromuscular blocking action may antagonize the effect of antimyasthenics on skeletal muscle; temporary dosage adjustments of antimyasthenics may be necessary to control symptoms of myasthenia gravis during and following concurrent use)

**Chloramphenicol or**
- Erythromycins
- (may displace clindamycin or lincomycin from or prevent their binding to 50 S subunits of bacterial ribosomes, thus antagonizing the effects of the lincosamides; concurrent use is not recommended)

**Opioid (narcotic) analgesics**
- (respiratory depressant effects of drugs with neuromuscular blocking action may be additive to central respiratory depressant effects of opioid analgesics, possibly leading to increased or prolonged respiratory depression or paralysis [apnea]; caution and careful monitoring of the patient are recommended)

**Laboratory value alterations**
- The following have been selected on the basis of their potential clinical significance (possible signs and, for humans, symptoms in parentheses where appropriate)—not necessarily inclusive (α = major clinical significance).
- **Note:** No significant laboratory value alterations have been reported in animals. Human laboratory value alterations have been reported and are included in this monograph.

**Human laboratory value alterations**
- The following laboratory value alterations have been reported in humans, and are included in the human monographs Clindamycin (Systemic) and Lincomycin (Systemic) in USP DI Volume I; these laboratory value alterations are intended for informational purposes only and may or may not be applicable to the use of clindamycin and lincomycin in the treatment of animals:
  - With physiology/laboratory test values
    - Alanine aminotransferase (ALT [SGPT]), serum, and Alkaline phosphatase, serum, and Aspartate aminotransferase (AST [SGOT]), serum (values may be increased)
- **Medical considerations/Contraindications**
  - The medical considerations/contraindications included have been selected on the basis of their potential clinical significance (reasons given in parentheses where appropriate)—not necessarily inclusive (α = major clinical significance).
  - **Risk-benefit should be considered when the following medical problems exist:**
    - Hepatic function impairment, severe (because clindamycin and lincomycin are metabolized by the liver; it is possible that severe hepatic function impairment could prolong the half-lives of these medications; adjustments in dosage might be required)
    - Hypersensitivity to clindamycin or lincomycin (sensitivity or cross-sensitivity may occur)
    - Renal function impairment, severe (lincomycin is eliminated by the kidneys of dogs to a greater degree than is clindamycin; very severe renal impairment may require dosage adjustments)
- **Patient monitoring**
  - The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition; α = major clinical significance):
    - Culture and susceptibility, in vitro, and
    - Minimum inhibitory concentration (MIC)
    - *(in vitro cultures and MIC tests should be done on samples collected prior to lincosamide administration to determine pathogen susceptibility)*
  - **Note:** The clindamycin disk is used for *in vitro* susceptibility testing to assess susceptibility to both clindamycin and lincomycin.
- **Side/Adverse Effects**
  - Note: The pseudomembranous colitis reported in people as an adverse reaction to lincosamides as well as the colitis and diarrhea side effects reported in chinchillas, guinea pigs, horses, rabbits, and ruminants are considered to be caused by overgrowth of resistant organisms. Resistant *Clostridium* species are suspected, but other organisms or even other mechanisms may also be involved.
  - The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and, for humans, symptoms in parentheses where appropriate)—not necessarily inclusive:
    - **Those indicating need for medical attention**
      - Incidence more frequent
        - *Chinchillas, guinea pigs, hamsters, horses, ponies, and rabbits* (anorexia; decreased milk production; diarrhea; ketosis)
        - *Enterocolitis* (anorexia; collapse; dehydration; diarrhea, watery and sometimes hemorrhagic)
      - Incidence less frequent
        - *Cats and dogs*
          - **Anorexia; diarrhea; vomiting**
          - **Note:** Anorexia, diarrhea, and vomiting in cats and dogs are believed to result from local irritation because side effects have not been seen with parenteral treatment. Side effects are more likely with higher doses.
        - **Ruminants**
          - With lincomycin—
            - **Anorexia; decreased milk production; diarrhea; ketosis**
            - **Note:** Anorexia, decreased milk production, ketosis, and severe diarrhea have been reported to be most likely in ruminants administered lincomycin orally.
            - However, some animals may develop adverse effects with parenterally administered lincomycin.
      - Incidence unknown
        - All species
          - **Hypersensitivity reactions**
            - *(sensitivity or cross-sensitivity may occur)*

© 2008 The United States Pharmacopeial Convention

All rights reserved
Those indicating need for medical attention only if they continue or are bothersome
Incidence more frequent
Cats
- Lip smacking—with clindamycin oral solution; [R-55] salivation—with clindamycin oral solution [R-85]
Incidence less frequent or rare
Pigs
- Anal swelling; [R-41; 42] diarrhea—transient; [R-41; 42] irritable behavior; [R-41; 42] skin reddening
Note: Anal swelling, diarrhea, irritable behavior, and skin reddening are generally self-limiting within 5 to 8 days.

Human side/adverse effects [R-44]
In addition to the above side/adverse effects reported in animals, the following side/adverse effects have been reported in humans, and are included in the human monographs Clindamycin (Systemic) and Lincomycin (Systemic) in USP DI Volume I; these side/adverse effects are intended for informational purposes only and may or may not be applicable to the use of clindamycin and lincomycin in the treatment of animals:
Incidence more frequent
- Gastrointestinal disturbances; pseudomembranous colitis
Incidence less frequent
- Fungal overgrowth; hypersensitivity; neutropenia; thrombocytopenia
Indicating possible pseudomembranous colitis and the need for medical attention if they occur after medication is discontinued
- Abdominal or stomach cramps and pain, severe; abdominal tenderness; diarrhea, watery and severe, which may also be bloody; fever

Overdose
For information in cases of overdose or unintentional ingestion, contact the American Society for the Prevention of Cruelty to Animals (ASPCA) National Animal Poison Control Center (888-426-4435 or 900-443-0000; a fee may be required for consultation) and/or the drug manufacturer.

Client Consultation
Medication should be administered for the full length of time prescribed. Any signs of anorexia, diarrhea, or vomiting should be reported to the veterinarian.

CLINDAMYCIN

Summary of Differences
Indications: Has a wider spectrum of activity than does lincomycin.
Pharmacology/pharmacokinetics: Highly absorbed after oral administration. Absorption is unaffected by the presence of food in the stomach.

Oral Dosage Forms
Note: The dosing and strengths of the dosage forms available are expressed in terms of the clindamycin base (not the hydrochloride salt). The text between [R-51] and [R-65] describes uses not included in U.S. product labeling. Text between [R-51; 53; 58] and [R-61; 65; 68] describes uses that are not included in Canadian product labeling. The [R-41; 42] or [R-51; 53; 58] designation can signify a lack of product availability in the country indicated. See also the Strength(s) usually available section for each dosage form.

CLINDAMYCIN HYDROCHLORIDE CAPSULES USP
Usual dose: See Clindamycin Hydrochloride Oral Solution USP; below in this monograph. Note that Clindamycin Hydrochloride Capsules USP are labeled for use in dogs only.

Strength(s) usually available:
Us. — [R-1; 6]
Veterinary-labeled product(s):
- 25 mg (base) (Rx) [Antirobe Capsules; Clincaps; ClindaCure Capsules; GENERIC].
- 75 mg (base) (Rx) [Antirobe Capsules; Clincaps; ClindaCure Capsules; GENERIC].
- 150 mg (base) (Rx) [Antirobe Capsules; Clincaps; ClindaCure Capsules; GENERIC].
- 300 mg (base) (Rx) [Antirobe Capsules; Clincaps; GENERIC].

Canada — [R-2; 6]
Veterinary-labeled product(s):
- 25 mg (base) (OTC) [Antirobe Capsules; nvClindamycin Capsules].
- 75 mg (base) (OTC) [Antirobe Capsules; nvClindamycin Capsules].
- 150 mg (base) (OTC) [Antirobe Capsules; nvClindamycin Capsules].

Packaging and storage: Store below 40 ºC (104 ºF), preferably between 15 and 30 ºC (59 and 86 ºF), unless otherwise specified by the manufacturer. Preserve in tight containers.

USP requirements: Preserve in tight containers. Contain an amount of clindamycin hydrochloride equivalent to the labeled amount of clindamycin, within –10% to +20%. Meet the requirements for Identification, Dissolution (80% in 30 minutes in phosphate buffer [pH 6.8] in Apparatus 1 at 100 rpm), Uniformity of dosage units, and Water (not more than 7.0%). [R-26]

CLINDAMYCIN HYDROCHLORIDE ORAL SOLUTION USP
Usual dose:
- Dental infections; or
- Anaerobic infections—
  Cats: Oral, 11 to 33 mg (base) per kg of body weight every twenty-four hours. [R-61; 53; 58]
  Dogs: Oral, 11 to 33 mg (base) per kg of body weight every twelve hours. [R-41; 58; 62]
- Osteomyelitis—Dogs: Oral, 11 to 33 mg (base) per kg of body weight every twelve hours. [R-1]
- Staphylococcal infections, including soft tissue infections and skin infections—
  Cats: Oral, 5.5 mg (base) per kg of body weight every twenty hours or 11 mg (base) per kg of body weight every twenty-four hours. [R-61; 53; 58]
  Dogs: Oral, 11 mg (base) per kg of body weight every twenty-four hours. [R-61; 53; 58]
For refractory infections, up to 33 mg (base) per kg of body weight every twelve hours may be administered. [R-1; 62]

Note: Osteomyelitis—[R-1; 53; 58]. Cats: Although the efficacy has not been established, an oral dose of 11 to 33 mg (base) per kg of body weight every twenty-four hours has been recommended. [R-53]

Toxoplasmosis—[R-51; 53; 58]. Cats: Although the efficacy has not been established, an oral dose of 12.5 to 25 mg (base) per kg of body weight every twelve hours for four weeks has been recommended. [R-57; 58; 53; 54; 57; 59]

Strength(s) usually available:
Us. — [R-6]
Veterinary-labeled product(s):
Usual dose: 25 mg (base) per mL (Rx) [Antirobe Aquadrops; ClindaCure Oral Liquid; Clinda-Guard Oral Liquid; Clindrops; Clinsol; Generic].

Veterinary-labeled product(s):
25 mg (base) per mL (Rx) [Antirobe Aquadrops].

Packaging and storage: Store below 40 ºC (104 ºF), preferably between 15 and 30 ºC (59 and 86 ºF), unless otherwise specified by the manufacturer. Protect from freezing.

USP requirements: Preserve in tight containers. Label oral solution to indicate that it is intended for veterinary use only. Contains the equivalent of the labeled amounts, within ±10%. Meets the requirements for Identification, Uniformity of dosage units, Deliverable volume, and pH (3.0–5.5).

CLINDAMYCIN HYDROCHLORIDE TABLETS

Usual dose: See Clindamycin Hydrochloride Oral Solution USP, above in this monograph. Note that Clindamycin Hydrochloride Tablets are labeled for use in dogs only.

Strength(s) usually available:
U.S.—[R-42]
Veterinary-labeled product(s):
25 mg (base) (Rx) [Clintabs].
75 mg (base) (Rx) [Clintabs].
150 mg (base) (Rx) [Clintabs].

Canada—Veterinary-labeled product(s):
Not commercially available.

Packaging and storage: Store below 40 ºC (104 ºF), preferably between 15 and 30 ºC (59 and 86 ºF), in a tight container, unless otherwise specified by the manufacturer.

USP requirements: Not in USP. [R-26]

LINCOMYCIN

Summary of Differences
Pharmacology/pharmacokinetics: Oral lincomycin is less well absorbed than intramuscular lincomycin; dosages are adjusted to compensate. Elimination of lincomycin is affected to a greater extent by severe renal function impairment than is clindamycin. Absorption is reduced by the presence of food in the stomach.

Oral Dosage Forms
Note: The dosing and strengths of the dosage forms available are expressed in terms of lincomycin base (not the hydrochloride salt).

The text between [R-38] and [R-42] describes uses not included in U.S. product labeling. Text between [R-42] and [R-42] describes uses that are not included in Canadian product labeling.

The [R-42] or [R-42] designation can signify a lack of product availability in the country indicated. See also the Strength(s) usually available section for each dosage form.

LINCOMYCIN HYDROCHLORIDE FOR MEDICATED FEED

Usual dose:

Growth promotion—

Chickens: Oral, 2 to 4 grams (base) per ton of feed, fed as the only ration. [R-38]

Withdrawal times—US and Canada: Meat—0 days.

Products are not labeled for use in chickens producing eggs for human consumption. [R-38; 42] Canadian product labeling states that the above withdrawal time applies when it is mixed at 2.2 grams of lincomycin per metric ton (1000 kg) of feed. [R-42]

EL-CAN [R-48]

Pigs: Oral, 20 grams (base) per ton of feed, fed as the only ration. [R-38]

Withdrawal times—US: Meat—0 days. [R-38]

Clincaps [R-48]

Necrotic enteritis—Chickens: Oral, 2 grams per ton of feed, fed as the only ration. [R-48]

Withdrawal times—US: Meat—0 days. Products are not labeled for use in chickens producing eggs for human consumption. [R-38]

Pneumonia, Mycoplasma—Pigs: Oral, 200 grams (base) per ton of feed, fed as the only ration for twenty-one days. [R-38]

Withdrawal times—US: Meat—0 days. [R-38]

Canada: Meat—2 days.

Porcine proliferative enteropathies (control)—Pigs: Oral, 100 grams (base) per ton of feed, fed as the only ration for twenty-one days or until signs of disease disappear. A dose of 40 grams (base) per ton of feed, fed as the only ration, may follow the above dose or be used in place of the 100-gram dose in animals that have not yet had symptoms. [R-38]

Withdrawal times—US and Canada: Meat—0 days. [R-38; 42]

Swine dysentery—Pigs: Oral, 40 grams (base) per ton of feed, fed as the only ration. [R-38; 42]

Treatment—Oral, 100 grams (base) per ton of feed (approximately 4.4 to 8.8 mg [base] per kg of body weight), fed as the only ration for twenty-one days or until signs of disease disappear. [R-38; 42]

Withdrawal times—US and Canada: Meat—0 days. [R-38; 42]

Strength(s) usually available:
U.S.—[R-42]
Veterinary-labeled product(s):
20 grams (base) per pound of premix (OTC) [Lincomix 20 Feed Medication].
50 grams (base) per pound of premix (OTC) [Lincomix 50 Feed Medication].

Canada—Veterinary-labeled products:
44 grams (base) per kg of premix (OTC) [Lincomix 44 Premix; Lincomycin 44G Premix].
110 grams (base) per kg of premix (OTC) [Lincomix 110 Premix; Lincomycin 110 Premix].

Packaging and storage: Store below 40 ºC (104 ºF), preferably between 15 and 30 ºC (59 and 86 ºF), unless otherwise specified by the manufacturer. Store in a dry place. [R-42]

Preparation of dosage form: Premix should be mixed into the complete feed following manufacturer’s directions to produce 2, 3, 4, 20, 40, 100, or 200 grams of lincomycin (base) per ton of feed.

Additional information:
Not for use in breeding swine or laying chickens. [R-38; 42]
In preparing feeds, appropriate cleanout procedures should be followed to prevent cross-contamination of other feeds. [R-42]

USP requirements: Not in USP. [R-26]

LINCOMYCIN HYDROCHLORIDE SOLUBLE POWDER USP

Usual dose:

Necrotic enteritis—Chickens: Oral, 64 mg (base) per gallon of water, administered as the only source of drinking water for seven days. [R-22; 28; 41; 96]

Withdrawal times—US and Canada: Meat—0 days. [R-29; 41]
Canadian product labeling states that the above withdrawal time applies when mixed at a concentration of 16 mg of lincomycin (base) per liter of water (61 mg per gallon). Unless otherwise specified by the manufacturer.

Swine dysentery—Pigs: Oral, 22 mg (base) per kg of body weight  every twenty-four hours for three to seven days. Withdrawal times—US and Canada: Meat—2 days. Canadian product labeling listing the above withdrawal time applies when mixed at a concentration of 33 mg of lincomycin (base) per liter of water (125 mg [base] per gallon).

Strength(s) usually available:

U.S. Veterinary-labeled product(s):
400 mg (base) per gram of powder [LicoMed Soluble Powder; Lincosol Soluble Powder; Generic].

Canada Veterinary-labeled product(s):
400 mg (base) per gram of powder [Lincosol Soluble Powder; Generic].

Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by the manufacturer.

Preparation of dosage form: Powder should be mixed into the drinking water following manufacturer’s directions to produce 61, 64, 125, or 250 mg (base) per gallon. Fresh stock solutions should be prepared on the day of use and unused medicated water discarded after 2 days.

USP requirements: Preserve in tight containers. Label it to indicate that it is for veterinary use only. Contains an amount of Lincomycin Hydrochloride equivalent to the labeled amount of lincomycin, within ±10%. Meets the requirements for Identification, Water, and Minimum fill.

LINCOMYCIN HYDROCHLORIDE SYRUP USP

Usual dose:

Skin infections**—Dogs: Oral, 22 mg (base) per kg of body weight every twelve hours or 15.4 mg (base) per kg of body weight every eight hours. Respiratory tract infections—Cats and dogs: Oral, 22 mg (base) per kg of body weight every twelve hours or 15.4 mg (base) per kg of body weight every eight hours.

Soft tissue infections—Cats and dogs: Oral, 22 mg (base) per kg of body weight every twelve hours or 15.4 mg (base) per kg of body weight every eight hours.

Strength(s) usually available:

U.S. Veterinary-labeled product(s):

Canada Veterinary-labeled product(s):

Packaging and storage: Store between 15 and 30 °C (59 and 86 °F), unless otherwise specified by the manufacturer.

USP requirements: Preserve in tight containers. Contains an amount of Lincomycin Hydrochloride equivalent to the labeled amount of lincomycin, within –10% to +20%, and one or more suitable colors, flavors, preservatives, and sweeteners in water. Meets the requirements for Uniformity of dosage units (for syrup packaged in single-unit containers), Deliverable volume (for syrup packaged in multiple-unit containers), and pH (3–5.5).

LINCOMYCIN HYDROCHLORIDE TABLETS

Usual dose:

Skin infections**—Dogs: Oral, 22 mg (base) per kg of body weight every twelve hours or 15.4 mg (base) per kg of body weight every eight hours.

Soft tissue infections**—Cats and dogs: Oral, 22 mg (base) per kg of body weight every twelve hours or 15.4 mg (base) per kg of body weight every eight hours.

Strength(s) usually available:

U.S.

Packaging and storage: Store between 15 and 30 °C (59 and 86 °F), unless otherwise specified by the manufacturer.

USP requirements: Not in USP.

Parenteral Dosage Forms

Note: The dosing and strengths of the dosage forms available are expressed in terms of lincomycin base (not the hydrochloride salt).

The text between ELUS and EL describes uses not included in U.S. product labeling. Text between ELCAN and EL describes uses that are not included in Canadian product labeling. The ELUS designation can signify a lack of product availability in the country indicated. See also the Strength(s) usually available section for each dosage form.

LINCOMYCIN INJECTION USP

Usual dose:

Joint infections, or

Pneumonia, Mycoplasma**—Pigs: Intramuscular, 11 mg (base) per kg of body weight every twenty-four hours for three to seven days. Withdrawal times—US and Canada: Meat—2 days. Canadian product labeling listing the above withdrawal time states that it applies to a dose of 10 mg per kg of body weight a day for three to seven days.

Skin infections**—Dogs: Intramuscular or intravenous, 22 mg (base) per kg of body weight every twenty-four hours or 11 mg (base) per kg of body weight every twelve hours.

Respiratory tract infections**—Cats and dogs: Intramuscular or intravenous, 22 mg (base) per kg of body weight every twenty-four hours or 11 mg (base) per kg of body weight every twelve hours.

Soft tissue infections**—Cats and dogs: Intramuscular or intravenous, 22 mg (base) per kg of body weight every twenty-four hours or 11 mg (base) per kg of body weight every twelve hours.

Note: For intravenous administration, the injection should be diluted with 5% glucose or normal saline and administered as a drip infusion. Swine dysentery**—Pigs: Intramuscular, 10 mg (base) per kg of body weight every twenty-four hours for three to seven
4. Lincomycin product information (Lincomix injection [swine], a preservative. Contains an amount of Lincomycin Hydrochloride Bacterial endotoxins, Sterility, pH (3.0–5.5), and Particulate lincomycin, within –10% to +20%. Meets the requirements for containers, preferably of Type I glass. Contains benzyl alcohol as 28, 2006.


27. Clindamycin product package insert (Cleocin HCL, Pharmacia—US), Rev 9/02, Rec 1/14/03.


29. Veterinary Advisory Panel meeting, 2/1/96.

32. DSD comment, 8/91.
40. Panel comment, 11/17/95.